Squibb & Sons

Bristol Myers Squibb is a premier global biopharmaceutical company that specializes in the discovery, development, and delivery of innovative medicines for serious diseases. The company's heritage traces back to 1858 with the founding of E.R. Squibb & Sons, which later merged with Bristol-Myers in 1989. Today, the organization is a leader in oncology, hematology, immunology, and cardiovascular medicine, boasting a portfolio of high-impact therapies such as Opdivo and Eliquis. Through aggressive R&D and strategic acquisitions like Celgene and Karuna Therapeutics, BMS continues to advance its pipeline in next-generation modalities including CAR-T cell therapies and targeted protein degradation.